Mucinous pancreatic neoplasms are uncommon disorders classified as either mucinous cystic neoplasms (mucinous cystadenoma or cystadenocarcinoma) or the more recently described intraductal mucin hypersecreting neoplasms (IMHN), also termed mucinous ductal ectasia. The mucinous cystic neoplasms share many common features with IMHN's but remain distinct clinico-pathologic entities. These tumors have similar histologic appearances, produce abundant mucin, are likely to masquerade as pancreatic pseudocysts, demonstrate a biologically less aggressive course compared to typical ductal adenocarcinomas, and are treated by surgical resection. Nevertheless, IMHN is characterized by intraductal tumor growth and mucin hypersecretion causing cystic transformation of the pancreatic duct and producing a distinct appearance on ERCP of mucus extrusion through a widely patent papilla and amorphous filling defects within the duct. In contrast, the mucinous cystic tumors are proposed to secrete mucin into a peripheral branch duct leading to a cyst cavity which does not communicate with the pancreatic duct and therefore is not demonstrated on pancreatography.
Introduction
Cystic abnormalities of the pancreas encompass a wide spectrum of disorders including non-neoplastic cysts such as true cysts in von Hippel-Lindau Disease and cystic fibrosis, congenital cysts, and pseudocysts and neoplastic lesions including serous cystadenomas, papillary cystic tumors, cystic islet cell tumors, mucinous cystic neoplasms (cystadenoma and cystadenocarcinoma), and intraductal mucin hypersecreting pancreatic neoplasms (IMHN) also termed "mucinous ductal ectasia" (MDE) ( Table 1) . Cystic neoplasms of the pancreas are rare, accounting for 10% of pancreatic cysts and 1% of pancreatic carcinomas [2] . The mucinous pancreatic neoplasms, mucinous cystic neoplasms and MDE, have recently attracted a great deal of interest leading to an improved understanding of their clinical and biologic behavior which has important implications for their proper diagnosis and management. Recent advances in diagnostic imaging such as ERCP, CT and US have led to a greater detection rate of these distinct clinicopathologic entities. Mucinous cystic neoplasms and MDE evolve from pancreatic duct epithelium, produce an abundance of mucin, are considered premalignant or malignant, and are likely to masquerade as pancreatic pseudocysts or pancreatitis. Mucinous cystic neoplasms primarily affect middle-aged women with lesions most commonly located in the pancreatic body and tail, in contrast to MDE which has a male predominance and is more often located in the pancreatic head. Histologically these tumors are indistinguishable. Nevertheless, the MDE tumors are differentiated from the classic mucinous cystic neoplasms due to recent advances in pancreas imaging, particularly ERCP. Mucinous ductal ectasia is characterized by intraductal tumor growth and cystic transformation of the duct system by mucin hypersecretion whereas the mucus in the mucinous cystic tumors is secreted and retained within a very peripheral parenchymal branch duct leading to formation of a cystic cavity which does not communicate with the main pancreatic duct [22] .
Intraductal mucin hypersecreting neoplasms "mucinous ductal ectasia"
Since the initial report in 1982 by Ohhashi et al [15] a host of papers have helped to define the clinicopathologic features of intraductal mucin hypersecreting neoplasms of the pancreas. The initial report described four patients with pancreatic carcinomas that were associated with unique clinical features distinct from the typical pancreatic ductal adenocarcinoma. There was intraductal excretion of mucin resulting in diffuse dilatation of the main pancreatic duct and extrusion of mucus through a patulous ampullary orifice, initially termed "mucin-producing pancreatic carcinoma". The tumor is an intraductal lesion rather than extraductal cyst cavity which secretes large quantitites of thick mucus into the duct lumen leading to partial pancreatic duct obstruction causing proximal dilatation and attacks of obstructive pancreatitis. The lesion has since been variably referred to as ductectatic mucinous cystadenoma or cystadenocarcinoma, mucin-hypersecreting carcinoma, intraductal papillary neoplasm, mucinous ductal ectasia, but would most appropriately be termed "intraductal mucin hypersecreting pancreatic neoplasm" (IMHN) to distinguish it from other pancreatic tumors which contain mucin on histopathologic examination but do not produce it in excess [4, 23] . It remains unlikely that this lesion represents a new pancreatic disorder but more likely reflects a process which has been better appreciated now that ERCP is more widely used in patients with unexplained pancreatitis. Subsequent to the initial report by Ohhashi more than 100 cases of mucin hypersecreting pancreatic neoplasms have been reported, primarily from Japan. Reports in the English literature are scarce due to a combination of poor recognition of this clinical entity and the rarity of the tumor. The true incidence of IMHN is not known because of limited awareness and the common tendency to misdiagnose these cases as chronic pancreatitis or mucinous cystic neoplasms [24] . Our experience at a single institution over the past three years has accumulated eight cases among 1500 ERCP's. This is likely to be an overestimation of its true incidence as the patient population evaluated is a highly selected group not representative of a general medical population. Nevertheless, we anticipate that greater attention and improved recognition will result in more frequent reporting and understanding of this lesion in the near future.
Clinical Features
The clinical presentation is characterized by chronic or recurrent attacks of abdominal discomfort often in association with low level pancreatic enzyme elevations mimicking chronic or relapsing pancreatitis [4, 14, 16, 18, 19, 23] . A history of pancreatitis was noted in four of the five patients reported by Itai et al [4 ] , in seven of nine patients in the series by Rickaert et al [19] , and in five of nine patients reported by Obara et al [14] . Serum pancreatic enzyme elevations may correlate with pain episodes, are typically only low level in magnitude, may be on an intermittent or consistent basis, and may be isolated to amylase and/or lipase [14, 16, 18, 19] . The episodes of pancreatitis are mild in severity based on well established grading systems such as APACHE or Ranson's criteria. Systemic (eg. ARDS, renal insufficiency) or local complications attributable to pancreatitis have not been reported. Largely as a result of the indolent nature of these tumors and the limited awareness of this lesion among the medical community, a delay in diagnosis ranging from months to years is not uncommon [7, 11, 14, 16] with a tendency to misdiagnose many of these patients as chronic pancreatitis, pancreatic pseudocysts, or cystic neoplasms. Less commonly these lesions may be detected as asymptomatic radiographic abnormalities or infrequently as abdominal masses detected on physical examination [11, 13, 16, 18] . Alternatively, pancreatic exocrine or endocrine insufficiency in the absence of abdominal pain may be the sole intital presentation in a minority of individuals [13] , although pancreatic insufficiency more typically develops as a late occurrence in the course of symptomatic disease in up to 50% [14, 23] . This is largely a disease of elderly individuals with a mean age of onset approximately 60 and a wide range of 40 to 85 years although in one case a woman as young as 30 years of age was affected [1, 5, 11, 13, 14, 16, 18, 23] . Amale predominance of 1.5:1 to 2:1 has been reported in most [5, 14, 16, 23] , but not all series [11] . Several patients manifest associated jaundice due to mucinous obstruction, fistulous tumor invasion or extrinsic compression of the distal common bile duct by lesions located in the pancreatic head [4, 18, 22, 23] .
Diagnostic Evaluation
ERCP is required for proper diagnosis as conventional imaging studies such as abdominal CT scanning and transabdominal ultrasonography reveal nonspecific changes indistinguishable from those of non-mucinous producing cystic neoplasms, chronic pancreatitis, and pancreatic pseudocysts. These non-ERCP imaging studies typically demonstrate well-defined unilocular or multilocular cystic pancreatic masses and/or dilatation of the main pancreatic duct [6, 14, 18, 23] . The cysts are not true cysts in that they represent dilated ductular structures. They are thin walled, non-septated, may contain excrescent tumor nodules, and are surrounded by normal or atrophic-appearing pancreatic parenchyma [4, 5, 6, 14] . The CT density is homogeneous and calcifications in the wall are not detected [5, 16, 18] . Angiography has not been helpful as hypervascularity, tumor blush, or vascular encasesment are rarely found [4, 5, 23, 16] . The typical pancreatogram (ERP) reveals extreme dilatation along the entire length of the main pancreatic duct with associated side branch ectasia in the absence of a demonstrable pancreatic duct stricture to explain the duct dilatation termed "duct ectatic" configuration ( Figure 1) [5, 14, 16, 18] . The cystically dilated portions of duct are filled with mucus and the dilatation is the result of mucus obstruction. The nature of the dilatation is typically smooth but a beaded appearance has been described [14] . The diameter of the main pancreatic duct is quite variable measuring up to 27mm in maximal diameter [4, 5, 14] . Alternatively, focal cystic dilatation of any portion of the main duct "main duct" type or its side branches "branch duct" pattern may give the appearance of a pancreatic pseudocyst or cystic neoplasm [22, 23] . When dilatation is focal in nature, the region of pancreatic duct dilatation is most commonly located in the head but may be limited to the body or tail in up to one-third of cases [14, 16, 19, 22, 23] . The "branch duct" pattern may give the appearance of clusters of small (l-2cm) thin-walled cysts [1, 5] . Localization to side branches to the uncinate process have also been reported [1, 5] . Well-defined intraductal tumor elevation is not generally seen except in the intraductal papillary and malignant forms described below. Intraductal mucus may be conspiciously absent in the intraductal papillary form, in which case ductal dilatation has been ascribed to tumorous rather than mucinous ductal obstruction [11, 12, 14] . The distinctive ERP feature found in most cases of IMHN is the presence of intraductal mucus observed either as visible mucus extruding thru a gaping major or minor ampulla, or as intraductal mucus plugs often demonstrated as linear, ovoid, or amorphous filling defects within the pancreatic duct [4, 23] . Due to the presence of abundant intraductal mucin, contrast injection into the pancreatic ductal system may be technically difficult. Adjuvant ERP techniques may be required to properly visualize the pancreatic duct system. We and others have noted greater ductal filling with deep cannulation, flushing of intraductal mucus from the system, and with the assistance of a balloon catheter to obtain an occlusion pancreatogram analogous to occlusion techniques for cholangiography [4, 14, 23] . In longterm follow-up of these patients, progressive ductal dilatation has been observed and transition may occur from a localized to diffuse form [13, 14] . Cyst wall calcification or intraductal calcified proteinaceous material as seen in cytic neoplasms and chronic pancreatitis, respectively, have not been described with these disorders [14, 23] . Sphincterotomy has anecdotally been reported to ameliorate pain and reduce pancreatic enzyme elevations presumably by fascilitating excretion of trapped mucus through the papilla [19] . Sphincterotomy and nasobiliary saline lavage have also been reported to relieve associated mucinous biliary obstruction and cholangitis [10] . Endoscopic ultrasonographic and intraductal endosonographic images of the intraductal pancreatic neoplasms have been reported but to date are not of proven value for diagnostic purposes nor in providing valuable information regarding tumor resectability [3] . Tissue specimens (aspiration cytology, brush cytology, or pancreatic biopsy] obtained endoscopically prior to surgery have a high false negative rate and are helpful only when postive [13, 14, 21, 23] . In the series by Obara et al [13, 14] , a histologic diagnosis was made prior to surgery in two patients with polypoid tumors of the main duct type by pancreatic ductal biopsy. In a report by Yamaguchi et al [23] a preoperative cytologic diagnosis was made in two of seven evaluated patients. Tada et al [21] performed brush cytology in 10 patients with mucin producing tumors of the pancreas. The brush cytology in the main duct type of carcinoma showed "cellular atypism" whereas the results in the patients with benign lesions were class I to HI. Intraductal biopsies from four of the patients with mucin producing carcinoma confirmed the presence of carcinoma in one and atypical hyperplasia in three. Our own experience with five patients revealed an intraductal biopsy specimen "suspicious for carcinoma" in a patient with intraductal carcinoma, and brush cytology specimens from the other four with dysplastic epithelium in three and no abnormalities in one [9] .
Pathology
Pathologically a spectrum of benign and malignant abnormalities have been described. In the most common benign cases, a flat mucosal lesion is found showing mucincontaining cystically dilated pancreatic ducts lined by ductular papillary hyperplasia or neoplastic, welldifferentiated mucinous columnar epithelium with or without prominent papillary growth. This lesion is histologically identical to the epithelium lining a mucinous cystadenoma [5, 14, 16, 22, 23] . The neoplastic lesion contains varying degrees of cellular atypia defined by irregular nuclear size, loss of nuclear polarity, nuclear hyperchromatism, rare mitotic figures, and pseudostratification also referred to as "atypical hyperplasia" [5, 19, 22] . The tumor cells stain intensively with PAS [19] . Immunocytochemical staining for CEA is weakly positive at the apical pole of tumor cells and CA 19-9 shows positive cytoplasmic staining [19] . However, serum levels of these tumor markers, CEA and CA 19-9, are typically within normal limits or only minimally elevated [7, 11, [12] [13] [14] 16, 23] . Two recent reports show that these intrductal neoplasms, in contrast to typical ductal adenocarcinomas, have negligible or low expression of the K-ras oncogene located on codon 12 [20] . In all cases the growth of the neoplastic columnar epithelium is restricted to the pancreatic duct wall with no invasion of pancreatic parenchyma or lymph nodes. This lesion is felt to have low malignant potential, although the true natural history of this lesion has not been well-defined due to the limited number of nonsurgically managed cases thus far reported. The tumor in the main duct type is primarily located inside the dilated main pancreatic duct but can extend into side branches and the tumor in the branch duct type is observed mainly inside the dilated branch ducts but can extend into the main duct to a lesser extent [22] . The extent of the flat mucosal lesion cannot be reliably determined intraoperatively complicating decisions regarding extent of operative pancreatic resection. The site of tumor involvement does not necessarily correspond to the region of dilated panceatic duct. When diffuse ductal dilatation is observed the lesion may be found in any portion of the main pancreatic duct although when focal duct dilatation is present the tumor is typically confined to the region of dilated main or side branch dilatation.
A second benign pathologic form termed intraductal papillary neoplasm shares many features with the flat intraductal mucosal lesion but is distinguished by the presence of a discretely elevated polypoid intraductal tumor and typically scant mucus production [11, 12, 17] . The tumor may be solitary or multiple with lesion size varying from one to several millimeters diameter. The clinical presentation, age distribution, histology, intraductal growth pattern, and immunocyochemistry make this tumor indistinguishable from the previously described benign flat mucosal cystadenoma type lesion [11, 12] . Furthermore, the surrounding main and branching pancreatic epithelium contains papillary and nonpapillary hyperplasia suggesting that this form may represent a natural progression from the flat mucosal lesion to polypoid tumor growth [19] .
Other reports describe malignant intraductal mucin producing neoplasms which are distinct pathologically but overlap clinically with the benign forms of IMHN in terms of mucin production, radiographic appearance, and their favorable prognosis compared to typical pancreatic ductal adenocarcinoma [5, 14, 22] . Even the malignant tumors largely consist of noncancerous mucinous papillary or atypical hyperplasia that surrounds the small area of cancerous tumor [22] . The histologic comparisions of the benign and malignant forms of IMHN may be analogous to mucinous megacystic disease with a natural progression of the benign variant to the more aggressive malignant cystadenocarcinoma. Yamada et al [22] suggest a sequential progression of ductular epithelium from nonpapillary hyperplasia through papillary and atypical hyperplasia and eventually to carcinoma. Similar to their benign counterparts, the vast majority of malignant tumors also present at a stage where tumor growth is confined to the pancreatic duct [4, 5, 8, 14] . Six of the nine patients described by Obara et al [14] had intraductal adenocarcinomas and only one showed invasive features with microscopic foci of periductal invasion. Such is not always the case however, as local invasion into the pancreatic parenchyma or surrounding structures of duodenum, lymph nodes or vascular structures such as the portal vein and less commonly distant metastases have been described [7, 22, 23] .
The surrounding adjacent pancreatic parenchyma shows a varying extent of fibrotic change in both benign and malignant forms. Chronic pancreatitis with acinar atrophy and fibrosis is limited to the obstructed portion of pancreatic duct. Thus, for cases with cystic dilatation disease confined to the pancreatic tail, the parenchymal fibrosis is restricted to this region. In contrast those with dilatation of the entire pancreatic duct have more extensive atrophy and fibrosis and thus are more likely to develop exocrine or endocrine pancreatic insufficiency in the course of their illness.
Prognosis and Therapy
The importance of diagnosing intraductal mucin hypersecreting neoplasms relates to their favorable prognosis and low malignant potential, a clear distinction from the typical ductal adenocarcinomas. Surgical treatment has included distal pancreatectomy for those with lesions confined to the pancreatic tail and Whipple resection or total pancreatectomy for dilatation confined to the head of the pancreas or involving the entire length of pancreatic duct [4, 14, 23] . During the Whipple resection, if mucinous epithelium is identified at the resection margin of the pancreas, the resection should be extended toward the tail until normal ductal mucosa is encountered. This is not a foolproof method as one patient in our experience with a benign flat ductal lesion and a negative resection margin on frozen section was found to have a positive margin on final pathologic diagnosis. The natural history of these disorders is not firmly defined as small numbers of cases have been reported and long-term followup is available in limited numbers. To date all patients with benign lesions are free from demonstrable recurrent disease [5, 14, 19, 23] . All six patients in the series by Rickaert et al. [19] are alive and well without evidence of tumor reucrrence or metastasis eight months to 10 years (mean 5.5 years) following surgical tumor resection. The four patients reported by Itai et al [5] are alive and without disease recurrence three to five years following operative resection.
Malignant lesions for the most part have also been cured by surgical resection [4, 5, 8, 14] but cases have nevertheless been described with incurable metastatic disease [18, 23] . Five of the six patients with malignant disease in the series by Obara et al [14] underwent operative resection and all but one are alive and without evidence of tumor recurrence 3-32 months following resection, including a patient with focal tumor invasion into pancreatic parenchyma. The other patient died of operative complications. All four patients reported by Itai et al [4] , with adenocarcinoma confined to the duct are alive and without recurrent disease 2 to 7.5 years after surgery. A fifth patient with malignant disease who was not resected was found to have intraperitoneal carcinomatosis at autopsy two years later. The usual criteria utilized to determine tumor resectability cannot be used strictly to determine operability with this lesion. For example, two patients with mucinous intraductal adenocarcinoma with local invasion of the duodenum and/or the portal vein are well and without evidence of disease recurrence 2.5 years following pancreaticoduodenectomy that included resection of the portal vein [7] .
Conclusions
Mucinous pancreatic neoplasms present a diagnostic and therapeutic challenge. These tumors behave in an indolent nature with frequent overlap of symptoms and radiographic appearance with other forms of pancreatic cysts, pseudocysts, and malignancy. Some authors propose that all mucin-producing tumors of the pancreas are variants of the same basic entity and have subclassified them on the basis of their predominant location within the pancreas [22] . These disorders must be considered in the evaluation of chronic abdominal pain particularly when in the presence of a cystic pancreatic lesion or when associated with idiopathic chronic or acute recurrent pancreatitis. The clinicopathologic features of IMHN overlap to a great extent with classic mucinous cystic neoplasms but are significantly different to be distinct clinical entities. These tumors originate from the pancreatic duct epithelium, produce mucin, demonstrate a papillary growth pattern, and are considered premalignant or frankly malignant at the time of diagnosis. Both lesions biologically are much less aggressive than that of pancreatic ductal adenocarcinoma and appear to infiltrate the peripancreatic tissue and to metastasize to lymph nodes or other adjacent structures late in the course of disease. Nevertheless, the IMHN's are primarily located in the head of the pancreas, commonly affect elderly men, and present clinically with obstructive pancreatitis often leading to pancreatic insufficiency, whereas mucinous cystic neoplasms are more likely to develop in the pancreatic body or tail, predominate in young women, and present with symptoms referable to tumor compression of adjacent structures. The location of the lesion is the primary differentiating feature as the lining epithelium of the two tumor types is pathologically indistinguishable. In the mucinous cystic tumors, the mucus is secreted and retained within the cyst lumen due to the absence of cummunication between the cyst and the main pancreatic duct. In contrast, mucus produced in MDE flows • into the main pancreatic duct resulting in obstructive pancreatitis and ultimately dilatation of the pancreatic duct. Intraductal mucus provides an important clue to the diagnosis of intraductal pancreatic neoplasms and whenever present should prompt an aggressive diagnostic evaluation. Both lesions are managed by resectional surgery as the opportunity for cure is high in the absence of metatstatic disease.
